778 related articles for article (PubMed ID: 18399807)
1. Immunohistochemical characteristics of melanoma.
Ohsie SJ; Sarantopoulos GP; Cochran AJ; Binder SW
J Cutan Pathol; 2008 May; 35(5):433-44. PubMed ID: 18399807
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
3. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
4. [Reactivity of five different antibodies with benign and malignant melanocytic lesions].
Plótár V; Szentirmay Z; Orosz Z
Magy Onkol; 2008 Dec; 52(4):363-73. PubMed ID: 19068464
[TBL] [Abstract][Full Text] [Related]
5. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma.
Gleason BC; Nascimento AF
Am J Dermatopathol; 2007 Feb; 29(1):22-7. PubMed ID: 17284958
[TBL] [Abstract][Full Text] [Related]
6. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA.
Sundram U; Harvell JD; Rouse RV; Natkunam Y
Mod Pathol; 2003 Aug; 16(8):802-10. PubMed ID: 12920225
[TBL] [Abstract][Full Text] [Related]
7. HMB-45 may be a more sensitive maker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas.
Yu CH; Chen HH; Liu CM; Jeng YM; Wang JT; Wang YP; Liu BY; Sun A; Chiang CP
J Oral Pathol Med; 2005 Oct; 34(9):540-5. PubMed ID: 16138892
[TBL] [Abstract][Full Text] [Related]
8. NGFR-positive desmoplastic melanomas with focal or absent S-100 staining: Further evidence supporting the use of both NGFR and S-100 as a primary immunohistochemical panel for the diagnosis of desmoplastic melanomas.
Radfar A; Stefanato CM; Ghosn S; Bhawan J
Am J Dermatopathol; 2006 Apr; 28(2):162-7. PubMed ID: 16625082
[TBL] [Abstract][Full Text] [Related]
9. Pigmented spindle cell nevus: clues for differentiating it from spindle cell malignant melanoma. A comprehensive survey including clinicopathologic, immunohistochemical, and FISH studies.
Díaz A; Valera A; Carrera C; Hakim S; Aguilera P; García A; Palou J; Puig S; Malvehy J; Alos L
Am J Surg Pathol; 2011 Nov; 35(11):1733-42. PubMed ID: 21997694
[TBL] [Abstract][Full Text] [Related]
10. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases.
de Almeida LS; Requena L; Rütten A; Kutzner H; Garbe C; Pestana D; Gomes MM
Am J Dermatopathol; 2008 Jun; 30(3):207-15. PubMed ID: 18496419
[TBL] [Abstract][Full Text] [Related]
11. KBA.62: a useful marker for primary and metastatic melanomas.
Pagès C; Rochaix P; al Saati T; Valmary-Degano S; Boulinguez S; Launay F; Carle P; Lauwers F; Payoux P; Le Guellec S; Brousset P; Lamant L
Hum Pathol; 2008 Aug; 39(8):1136-42. PubMed ID: 18495211
[TBL] [Abstract][Full Text] [Related]
12. [Distribution of melanoma-associated antigens (HMB 45 and S 100) in benign and malignant melanocytic tumors of the conjunctiva].
Steuhl KP; Rohrbach JM; Knorr M
Klin Monbl Augenheilkd; 1991 Sep; 199(3):187-91. PubMed ID: 1753671
[TBL] [Abstract][Full Text] [Related]
13. S100, HMB-45, and Melan-A negative primary melanoma.
Shinohara MM; Deubner H; Argenyi ZB
Dermatol Online J; 2009 Sep; 15(9):7. PubMed ID: 19930994
[TBL] [Abstract][Full Text] [Related]
14. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma.
Granter SR; Weilbaecher KN; Quigley C; Fletcher CD; Fisher DE
Am J Dermatopathol; 2001 Jun; 23(3):185-9. PubMed ID: 11391097
[TBL] [Abstract][Full Text] [Related]
15. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
Fröhlich E; Mack AF; Garbe C; Klessen C
Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma.
Abdou AG; Hammam MA; Farargy SE; Farag AG; El Shafey EN; Farouk S; Elnaidany NF
Am J Dermatopathol; 2010 Dec; 32(8):809-14. PubMed ID: 20885286
[TBL] [Abstract][Full Text] [Related]
17. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
18. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations.
Sheffield MV; Yee H; Dorvault CC; Weilbaecher KN; Eltoum IA; Siegal GP; Fisher DE; Chhieng DC
Am J Clin Pathol; 2002 Dec; 118(6):930-6. PubMed ID: 12472287
[TBL] [Abstract][Full Text] [Related]
19. S-100 protein-negative malignant melanoma: fact or fiction? A light-microscopic and immunohistochemical study.
Argenyi ZB; Cain C; Bromley C; Nguyen AV; Abraham AA; Kerschmann R; LeBoit PE
Am J Dermatopathol; 1994 Jun; 16(3):233-40. PubMed ID: 7943629
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical evaluation of necrotic malignant melanomas.
Nonaka D; Laser J; Tucker R; Melamed J
Am J Clin Pathol; 2007 May; 127(5):787-91. PubMed ID: 17439838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]